KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables - Net: 2009-2025

Historic Receivables - Net for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $346.0 million.

  • Halozyme Therapeutics' Receivables - Net rose 21.10% to $346.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $346.0 million, marking a year-over-year increase of 21.10%. This contributed to the annual value of $308.5 million for FY2024, which is 31.70% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Receivables - Net stood at $346.0 million for Q3 2025, which was up 9.39% from $316.3 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Receivables - Net peaked at $346.0 million during Q3 2025, and registered a low of $89.5 million during Q1 2021.
  • Its 3-year average for Receivables - Net is $260.9 million, with a median of $246.2 million in 2023.
  • In the last 5 years, Halozyme Therapeutics' Receivables - Net skyrocketed by 304.02% in 2021 and then dropped by 12.86% in 2024.
  • Halozyme Therapeutics' Receivables - Net (Quarterly) stood at $92.1 million in 2021, then soared by 150.85% to $231.1 million in 2022, then rose by 1.36% to $234.2 million in 2023, then skyrocketed by 31.70% to $308.5 million in 2024, then increased by 21.10% to $346.0 million in 2025.
  • Its last three reported values are $346.0 million in Q3 2025, $316.3 million for Q2 2025, and $304.6 million during Q1 2025.